Astra pays up to $1.2 billion for arthritis drug
- February 17, 2010
AstraZeneca waded into the competitive rheumatoid arthritis market on Tuesday by buying rights to Rigel Pharmaceuticals‘ next-generation drug R788 for up to $1.245 billion, Reuters reported. The deal is a big ... Read More